Hematology Today—May 4, 2026

This week’s Hematology update highlights regulatory progress, clinical data readouts, pipeline advancements, and strategic deals shaping treatment landscapes

Dive deeper

🩸 IMAAVY Priority Review in wAIHA [1] [US • 27 Apr 2026]

https://www.jnj.com/media-center/press-releases/fda-grants-priority-review-for-imaavy-nipocalimab-aahu-as-the-potential-first-approved-treatment-for-people-living-with-warm-autoimmune-hemolytic-anemia-waiha
Context: IMAAVY (Johnson & Johnson; nipocalimab-aahu) is an FcRn blocker under FDA review for warm autoimmune hemolytic anemia.
Key point: FDA granted Priority Review to the sBLA, supported by Phase 2/3 ENERGY data showing durable hemoglobin response and fatigue improvement.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Sovleplenib China NDA accepted in wAIHA [2] [China • 29 Apr 2026]

https://www.hutch-med.com/sovleplenib-waiha-china-nda/
Context: Sovleplenib (HUTCHMED; oral Syk inhibitor) is proposed for adults with wAIHA after insufficient glucocorticoid response.
Key point: China NMPA accepted the NDA and granted Priority Review; Breakthrough Therapy Designation was granted in Mar 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 Jakafi XR approved for MF, PV, and GVHD [3] [US • 01 May 2026]

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-fda-approval-jakafi-xrtm-ruxolitinib-extended
Context: Jakafi XR (Incyte; ruxolitinib extended-release) is a once-daily formulation of Jakafi.
Key point: FDA approved Jakafi XR for adults with intermediate- or high-risk MF, adults with PV after hydroxyurea, and eligible acute or chronic GVHD patients.
Implication: Could streamline initiation and adherence through a once-daily option.

🎯 TERN-701 Breakthrough Therapy Designation in CML [4] [US • 27 Apr 2026]

https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-announces-fda-breakthrough-therapy
Context: TERN-701 (Terns Pharmaceuticals; oral allosteric BCR::ABL1 inhibitor) is being studied in the Phase 1/2 CARDINAL trial.
Key point: FDA granted Breakthrough Therapy Designation for Ph+ chronic-phase CML without T315I mutation after two or more TKIs.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Nadunolimab early MDS and AML results [5] [27 Apr 2026]

https://cantargia.com/en/press-releases/cantargia-announces-early-results-from-trial-of-nadunolimab-in-mds-and-aml
Context: Nadunolimab (Cantargia; IL1RAP antibody) is being studied with azacitidine in high-risk MDS and with azacitidine plus venetoclax in AML.
Key point: Phase 1b dose escalation completed; all five efficacy-evaluable high-risk MDS patients achieved complete remissions.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Orca-Q RMAT designation in high-risk hematologic malignancies [6] [US • 28 Apr 2026]

https://orcabio.com/orca-bio-announces-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-orca-q-for-the-treatment-of-high-risk-hematologic-malignancies/
Context: Orca-Q (Orca Bio; investigational allogeneic T-cell immunotherapy) is in Phase 1 for hematologic malignancies.
Key point: FDA granted RMAT designation based on preliminary Phase 1 findings across survival, GVHD, and non-relapse mortality.
Implication: Signals pipeline investment and modality expansion.

⚠️ HyBryte FLASH2 futility recommendation in CTCL [7] [US • 28 Apr 2026]

https://ir.soligenix.com/2026-04-28-Soligenix-Announces-Interim-Results-from-the-Phase-3-FLASH2-Trial-Evaluating-HyBryte-TM-in-Treatment-of-Cutaneous-T-Cell-Lymphoma
Context: HyBryte (Soligenix; synthetic hypericin photodynamic therapy) was in the pivotal Phase 3 FLASH2 trial for CTCL.
Key point: The Data Monitoring Committee recommended halting FLASH2 for futility after interim efficacy analysis.
Implication: May reshape development priorities and regulatory discussions.

🧲 ELREXFIO Phase 3 PFS win in RRMM [8] [29 Apr 2026]

https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elrexfio-significantly-improves-progression-free
Context: ELREXFIO (Pfizer; elranatamab, BCMA-CD3 bispecific) was tested in Phase 3 MagnetisMM-5 in relapsed or refractory multiple myeloma.
Key point: ELREXFIO monotherapy significantly improved PFS versus daratumumab plus pomalidomide and dexamethasone.
Implication: May influence prescriber choice and payer reviews pending full data.

🧒 Expression Therapeutics dual FDA designations in hemophilia A [9] [US • 29 Apr 2026]

https://www.prnewswire.com/news-releases/expression-therapeutics-receives-fda-fast-track-and-rare-pediatric-disease-designations-for-investigational-stem-cell-therapy-for-hemophilia-a-302756492.html
Context: Expression Therapeutics is developing an investigational autologous stem cell therapy for hemophilia A.
Key point: FDA granted Fast Track and Rare Pediatric Disease designations; Phase 1 data supported advancement to Phase 2.
Implication: Signals pipeline investment and modality expansion.

🤝 Lilly to acquire Ajax Therapeutics [10] [US • 27 Apr 2026]

https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ajax-therapeutics-advance-outcomes-patients
Context: Ajax Therapeutics’ AJ1-11095 is a once-daily, oral, Type II JAK2 inhibitor in Phase 1 for myelofibrosis.
Key point: Lilly agreed to acquire Ajax, with shareholders eligible for up to $2.3B in cash including milestones.
Implication: Signals pipeline investment and modality expansion.

Why it matters

wAIHA saw two regulatory advances in one week, with Johnson & Johnson in the US and HUTCHMED in China.
JAK pathway activity stayed prominent across approval, investigational, and M&A updates.
Cell and gene therapy momentum continued through Orca-Q and Expression Therapeutics designations.
Late-stage risk remained visible, as Soligenix’s CTCL program received a futility recommendation.
Multiple myeloma competition may intensify if ELREXFIO’s MagnetisMM-5 data support earlier-line use.

🎯 Catch up on the Top Hematology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

FAQ

What happened with IMAAVY in wAIHA?

FDA granted Priority Review to Johnson & Johnson’s sBLA for IMAAVY (nipocalimab-aahu) in wAIHA. The review is supported by Phase 2/3 ENERGY data, with full results planned for a medical conference. [1]

How does sovleplenib differ from IMAAVY?

Sovleplenib (HUTCHMED) is an oral Syk inhibitor under China NMPA review for wAIHA. IMAAVY (Johnson & Johnson) is an FcRn blocker under FDA review for wAIHA. [1], [2]

What did FDA approve for Jakafi XR?

FDA approved Jakafi XR (ruxolitinib extended-release) for MF, PV, and certain acute or chronic GVHD patients. The formulation is once daily. [3]

What is the main ELREXFIO MagnetisMM-5 result?

Pfizer said ELREXFIO met the Phase 3 MagnetisMM-5 primary endpoint, improving PFS versus daratumumab plus pomalidomide and dexamethasone. Overall survival was not mature. [8]

Why is the HyBryte update negative?

Soligenix said the FLASH2 Data Monitoring Committee recommended halting the CTCL trial for futility. The company plans to analyze the dataset and assess next steps. [7]

What is Lilly buying with Ajax Therapeutics?

Lilly is acquiring Ajax Therapeutics to add AJ1-11095, a Phase 1, once-daily, oral Type II JAK2 inhibitor for myelofibrosis and potentially other MPNs. [10]

Entities / Keywords

Johnson & Johnson, Janssen, IMAAVY, nipocalimab-aahu, FcRn, wAIHA, ENERGY
HUTCHMED, sovleplenib, Syk inhibitor, NMPA, wAIHA, ESLIM-02
Incyte, Jakafi XR, Jakafi, ruxolitinib, MF, PV, GVHD
Terns Pharmaceuticals, TERN-701, BCR::ABL1, Ph+ CML, CARDINAL
Cantargia, nadunolimab, CAN04, IL1RAP, MDS, AML
Orca Bio, Orca-Q, RMAT, allogeneic T-cell immunotherapy, GVHD
Soligenix, HyBryte, SGX301, synthetic hypericin, FLASH2, CTCL
Pfizer, ELREXFIO, elranatamab, MagnetisMM-5, BCMA-CD3, RRMM
Expression Therapeutics, hemophilia A, autologous stem cell therapy, Factor VIII
Eli Lilly, Ajax Therapeutics, AJ1-11095, Type II JAK2 inhibitor, AJX-101, MPNs